Arthur Horwich and Franz-Ulrich Hartl honored for contributions to the understanding of the molecular mechanism of protein folding.
The Shaw Prize Foundation in Hong Kong today announced that Arthur Horwich, a Howard Hughes Medical Institute investigator at Yale University, and Franz-Ulrich Hartl of the Max Planck Institute of Biochemistry have been awarded the Shaw Prize in Life Science and Medicine. The two were honored for their contributions to the understanding of the molecular mechanism of protein folding.
The Shaw Prize consists of three annual awards in astronomy, life science and medicine, and mathematical sciences. These international awards honor individuals who have achieved distinguished breakthroughs in academic and scientific research. The awards are dedicated to furthering societal progress, enhancing quality of life, and enriching humanity's spiritual civilization. The 2012 prizes will be presented to recipients later this year at a ceremony in Hong Kong. Each prize carries a $1 million monetary award.
The Shaw Prizes were established under the auspices of Sir Run Run Shaw, a Hong Kong film producer and chairman of Television Broadcasts Limited (TVB), the largest Chinese program producer in the world. The Shaw Prize is accompanied by a medal displaying a portrait of Sir Run Run Shaw and the imprint of a Chinese phrase that translates as "Grasp the law of nature and make use of it."
Horwich and Hartl are being honored for discovering that proteins cannot fold inside cells by themselves. They determined that a protein—dubbed "chaperonin" because of its assisting role—acts as a cage-like folding "machine" that provides a safe place for proteins to fold, away from outside interference.
Proteins are vital to life, and the physical shape of a protein determines how it works. Proteins consist of chains of amino acids that fold to form their three-dimensional structures. Scientists often seek to understand the way a protein's architecture impacts a cell's physiology or how altered proteins cause disease.
In 1972, Christian Anfinsen shared a Nobel Prize in Chemistry for research from the 1950s showing that the linear sequence of the amino acids of a protein contains the information the molecule needs to form its functional shape. He unfolded an enzyme in a test tube, and the biomolecule re-formed correctly.
But by the late 1980s, Horwich and Hartl and other scientists were questioning whether the amino acid sequence alone was sufficient to direct proper protein folding in the cell. Evidence was accumulating that under stressful conditions, such as excess heat, cells use inducible "heat-shock proteins" as protective agents. These proteins appear to prevent or reverse the damaging multiprotein aggregation that can occur when excessive heat melts a protein's structure. But do cells use similar assistance under normal conditions?
In late 1987, Horwich and his group stumbled onto a yeast mutant that ultimately demonstrated such assistance was occurring. It became clear over the subsequent year that a cellular machine they had discovered, a large cylindrical assembly called a chaperonin, itself a heat-shock protein, is required for the proper folding of many proteins under normal conditions in the living cell. The amino acid sequence determined the proper fold of these proteins, as inferred by Anfinsen, but a chaperonin also was needed.
Horwich and his coworkers have studied the mechanism of chaperonin assistance ever since. The machine helps at two levels. First, the cylinder's open ring selectively binds an unfolded protein's "greasy" surface, which eventually becomes buried in the folded state. Protein binding to the chaperonin prevents misfolding and aggregation. Second, a lid structure, a second protein called a co-chaperonin, is added to the open ring, thus encapsulating the unfolded protein and allowing it to fold in solitary confinement, without the possibility of aggregation, following Anfinsen's principles. After 10 seconds, the lid pops off and out comes the properly folded protein, like a jack-in-the-box.
Horwich came to research with a clinical background. He was valedictorian of his medical school class at Brown University, but became intrigued during his pediatric residency at Yale by a genetic experiment: a single gene from a polyoma virus could turn a normal cell cancerous. How did it do this?
Pursuing his curiosity, Horwich went to The Salk Institute as a postdoctoral fellow to work with Walter Eckhart and Tony Hunter, who studied polyoma virus cancer transformation. Horwich watched Hunter make a spectacular discovery. Hunter, who had decided to study virus-encoded proteins that have attached phosphate groups, ran an electrophoresis separation late one night with old buffer. He observed a new phosphoamino acid spot never before seen. Recognizing it as a phosphate added to tyrosine, Hunter went on to show that tyrosine kinases and phosphorylation are key regulators of cell growth.
Having experienced the excitement of experimental inquiry, and wanting to marry his interests in molecular biology and medicine, Horwich returned to Yale in 1981 for further postdoctoral training in medical genetics with Leon Rosenberg. While there, Horwich, Rosenberg, and coworkers cloned the coding sequence for human ornithine transcarbamylase (OTC), an enzyme that detoxifies waste nitrogen by converting ammonia to urea. X-linked deficiency of OTC often leads to ammonia intoxication in affected newborn males, who appear normal a day or two after birth but then lapse into irreversible coma. The sequence offered the possibility of DNA diagnosis for affected families.
But how the cell made OTC also fascinated Horwich. The enzyme subunit, encoded by the X chromosome, was produced in the cytoplasm as a precursor, and then imported across the two mitochondrial membranes to the innermost matrix. Horwich decided to use yeast genetics to identify the steps in the process. Initially, he showed that his cloned human OTC expressed in yeast went to its mitochondria and became enzymatically active. The first mutants he found in the pathway blocked maturation of the OTC precursor to its mature size.
Then he and his student Ming Cheng had a prescient thought late one night after a day of mutant screening. It was known that proteins unfold to cross mitochondrial membranes. Everyone assumed they then spontaneously refolded to the active form. But what if a "machine" helped the refolding? After all, protective heat-shock proteins maintained protein conformations. What if there were machines that assisted folding under normal conditions? A mutant affecting such a machine would allow import into the mitochondrion of a mature-sized OTC enzyme, but it would have no activity.
They soon found such a mutant. Skeptical of their result, they performed multiple experiments to assess whether normal yeast mitochondrial proteins also were affected in the mutant. Every experiment, and later ones with collaborators from Munich, confirmed the result. They then identified the gene affected in the mutant. This gene turned out to encode a mildly heat-inducible mitochondrial protein, dubbed heat-shock protein 60, or Hsp60, which also functions at normal temperatures. Hsp60 is the subunit component that makes up the chaperonin complex.
Over the years, Horwich has continued to study the machine, but working on a more easily manipulable bacterial version, called GroEL. The genetic studies proceeded to biochemical studies, in collaboration with Franz-Ulrich Hartl; then to crystallographic studies, in collaboration with the late Paul Sigler, an HHMI investigator at Yale; to electron micrograph studies with Helen Saibil at Birkbeck College London; to structure-function studies with Wayne Fenton at Yale; and later to NMR studies with Kurt Wüthrich at ETH Zurich. The result of these collaborative efforts is a dynamic view of the working cycle of this protein-folding machine.